Cardiol Therapeutics announced that Phase II MAvERIC results in recurrent pericarditis were accepted for publication in JAHA. The company also provided updates on its Phase III MAVERIC trial, published ARCHER trial results, and CRD-38 development.
Cardiol Therapeutics announced the publication of its Phase II MAvERIC study results in the Journal of the American Heart Association. The study showed CardiolRx led to rapid and sustained reductions in pericarditis pain and inflammation with a favorable safety profile. The findings support the ongoing Phase III MAVERIC trial.
Invivyd reported progress in the Phase 3 DECLARATION trial of VYD2311, with top-line data now expected in Q3 2026 after a sample size increase of about 500 subjects. The company also aligned with the FDA on the LIBERTY Phase 3 study, a pediatric study plan for DRUMMER, and advanced measles antibody candidate VMS063.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07716696 |
Effects of Pulmonary Rehabilitation Versus Standard Care in Patients With Pericarditis |
ACTIVE_NOT_RECRUITING | NA |
| NCT07288216 |
Transition to KPL-387 Monotherapy Dosing & Administration Study |
RECRUITING | PHASE2 |
| NCT07077304 |
EACVI Study on Multimodality Cardiovascular Imaging of Inflammatory Cardiovascular Diseases |
RECRUITING | |
| NCT07010159 |
Phase 2/3 Study of KPL-387 in Recurrent Pericarditis |
RECRUITING | PHASE2/PHASE3 |
